Advertisement
Research Article Free access | 10.1172/JCI107695
1Cardeza Foundation and the Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Find articles by Smith, J. in: JCI | PubMed | Google Scholar
1Cardeza Foundation and the Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Find articles by Ingerman, C. in: JCI | PubMed | Google Scholar
1Cardeza Foundation and the Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Find articles by Kocsis, J. in: JCI | PubMed | Google Scholar
1Cardeza Foundation and the Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Find articles by Silver, M. in: JCI | PubMed | Google Scholar
Published May 1, 1974 - More info
A compound that could be converted to prostaglandin F2α by mild chemical reduction was formed by human platelets in response to arachidonic acid, collagen, or L-epinephrine. It was present in maximal amounts at about 1 min after addition of arachidonic acid or collagen to platelet-rich plasma. Its initial formation appeared to precede platelet aggregation by these agents and was closely correlated with the release of adenine nucleotides and radioactive 5-hydroxytryptamine from platelets. Moreover, the compound was itself found outside the platelets. This compound is probably an endoperoxide intermediate in prostaglandin biosynthesis and may be a trigger for the platelet release reaction.